# Division of Medical Assistance Pancreas Transplantation

Clinical Coverage Policy No. 11B-7 Original Effective Date: January 1, 1994 Revised Date: December 1, 2005

# Introduction

Transplantation is the procedure involving the removal of a bodily organ or tissue from one person, and the insertion of that organ or tissue into another person to replace a damaged organ or tissue.

#### **Definition of Terms:**

Allograft – transplant from one individual to another (synonymous with homograft)
Hereotopic graft – transplant placed in a site different than the organ's normal location
Orthotopic graft – transplant placed in its normal anatomical site
Syngeneic graft (isograft) – transplant between identical twins
Xenograft – transplant between different species

Organ transplantation is now well established as an effective treatment for selected patients with endstage organ failure. Transplantation of the kidney, liver, pancreas, heart, and lungs are all routine procedures, and transplantation of the small intestine is becoming more widely practiced. Currently, transplant activity is limited only by the shortage of cadaveric organs.

The following policy contains the minimal criteria for solid organ transplants. Additional justification may be required at the discretion of the Division of Medical Assistance Hospital Consultant staff.

#### 1.0 Definition of the Procedure

Pancreas transplant (PTA), simultaneous pancreas kidney (SPK), and simultaneous cadaverdonor pancreas and living donor kidney (SPLK) procedures involve the removal of diseased organs (pancreas or pancreas/kidney) from the recipient and replacing them with healthy organs from a deceased or living donor.

# 2.0 Eligible Recipients

## 2.1 General Provisions

Medicaid eligible individuals with a need for this specialized treatment confirmed by a licensed physician are eligible as long as they meet individual eligibility requirements. Medicaid recipients may have service restrictions due to their eligibility category, which would make them ineligible for this service.

#### 2.2 Special Provisions

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that provides recipients under the age of 21 with medically necessary health care to correct or ameliorate a defect, physical or mental illness or a condition identified through a screening examination. While there is no requirement that the service, product or procedure be included in the State Medicaid Plan, it must be listed in the federal law at 42 U.S.C. § 1396d(a). Service limitations on scope, amount or frequency described in this coverage policy do not apply if the product, service or procedure is medically necessary.

The Division of Medical Assistance's policy instructions pertaining to EPSDT are available online at <a href="http://www.dhhs.state.nc.us/dma/prov.htm">http://www.dhhs.state.nc.us/dma/prov.htm</a>.

CPT codes, descriptors, and other data only are copyright 2004 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## 3.0 When the Procedure is Covered

Each recipient's condition is evaluated on an individual basis. There may be other conditions that are indications for coverage.

The N.C. Medicaid program covers PTA, SPK, and SPLK for patients who meet <u>ALL</u> of the following criteria:

#### 3.1 PTA

- 1. history of labile (brittle) insulin-dependent diabetes mellitus (IDDM)
- 2. recurrent and acute life threatening metabolic complications:
  - a. hypoglycemia
  - b. hyperglycemia
  - c. ketoacidosis
  - d. hypoglycemic unawareness with high risk of injury
- 3. consistent failure of exogenous insulin management
  - a. HbA1C of 8.0 or > documented with aggressive conventional management (insulin pump, adjusting of amounts and frequencies of insulin injected, multiple daily blood glucose levels, and strict diet and exercise).
- 4. satisfactory kidney function (creatinine clearance > 40ml/min)
- 5. adequate cardiac status

#### 3.2 SPK and SPLK

- 1. type 1 insulin-dependent (juvenile onset) diabetes
- 2. ESRD requiring dialysis or expected to require dialysis in the next 12 months
- 3. one type of progressive secondary diabetic complication, which is more serious than the risk of major surgery and immunosuppression
- 4. glucose levels 300mg/dl or more with a C-peptide level of 0.2ng/ml or less
- 5. creatinine clearance calculated by Cockcroft-Gault < 30ml/min

## 4.0 When the Procedure is Not Covered

Pancreas transplant is not covered when the medical necessity criteria listed in **Section 3.0** are not met. Each recipient's condition is evaluated on an individual basis. There may be other conditions that are indications for non-coverage.

The N.C. Medicaid program does not cover pancreas transplant when one of the following conditions exist (not all inclusive):

#### 4.1 Allogeneic and Xeno Islet Cell Transplants

Allogeneic and Xeno islet cell transplants are not covered for any diagnosis.

#### 4.2 PTA

- 1. active infection
- 2. HIV positive
- 3. history of malignancy within five years
- 4. history of or active substance abuse must have documentation of substance abuse program completion plus six months of negative sequential random drug screens

**Note:** To satisfy the requirement for sequential testing as designated in this policy, the Division of Medical Assistance (DMA) must receive a series of test (alcohol and drug) results spanning a minimum six-month period, allowing no fewer than a three-week interval and no more than six-week interval between each test during the given time period. A complete clinical packet for prior approval must include at least one documented test performed within one month of the date of request to be considered.

- 5. psychosocial history that would limit ability to comply with medical care pre and post transplant
- 6. morbid obesity
- 7. current patient and/or caretaker non-compliance that would make compliance with a disciplined medical regime improbable
- 8. ejection fraction < 40%
- 9. myocardial infarction within last six months
- 10. uncontrolled hypertension
- 11. severe peripheral vascular disease

#### 4.3 SPK and SPLK (Absolute)

- 1. un-reconstructable coronary artery disease, or refractory CHF
- 2. cancer within last five years
- 3. current patient and/or caretaker non-compliance that would make compliance with a disciplined medical regime improbable
- 4. morbid obesity
- 5. psychosocial history that would limit ability to comply with medical care pre and post transplant
- 6. history of or active substance abuse must have documentation of substance abuse program completion plus six months of negative sequential random drug screens

**Note:** To satisfy the requirement for sequential testing as designated in this policy, DMA must receive a series of test (alcohol and drug) results spanning a minimum six-month period, allowing no fewer than a three-week interval and no more than six-week interval between each test during the given time period. A complete clinical packet for prior approval must include at least one documented test performed within one month of the date of request to be considered.

7. HIV positive

# 4.4 SPK and SPLK (Relative contraindications)

- 1. cardiac disease: EF < 40%, MI within last six months
- 2. chronic liver disease
- 3. severe peripheral vascular disease
- 4. severe cerebrovascular disease
- 5. uncontrolled hypertension
- 6. age 65 years or older

#### 4.5 Donors

Living donor expenses are not covered for a pancreas transplant.

# 5.0 Requirements for and Limitations on Coverage

All applicable N.C. Medicaid policies and procedures must be followed in addition to the ones listed in this procedure.

All procedures must be prior approved by DMA.

# 6.0 Providers Eligible to Bill for the Procedure

Physicians enrolled in the N.C. Medicaid program who perform this procedure may bill for this service.

# 7.0 Additional Requirements

FDA approved procedures, products, and devices for implantation must be utilized.

Implants, products, and devices must be used in accordance with all FDA requirements current at the time of surgery.

A statement signed by the surgeon certifying all FDA requirements for the implants, products, and devices must be retained in the recipient's medical record and made available for review upon request.

# 9.0 Policy Implementation/Revision Information

Original Effective Date: January 1, 1994

#### **Revision Information:**

| Date    | Section Revised | Change  |  |
|---------|-----------------|---|--|
| 7/1/05  | Entire Policy   | Policy was updated to include coverage criteria effective |  |
|         |                 | with approved date of State Plan amendment 4/1/05.        |  |
| 9/1/05  | Section 2.2     | The special provision related to EPSDT was revised.       |  |
| 12/1/05 | Section 2.2     | The web address for DMA's EDPST policy instructions       |  |
|         |                 | was added to this section.                                |  |
|         |                 |   |  |
|         |                 |   |  |
|         |                 |   |  |

# **Attachment A Claims Related Information**

Reimbursement requires compliance with all Medicaid guidelines including obtaining appropriate referrals for recipients enrolled in the Medicaid Managed Care programs.

# A. Claim Type

- 1. Physicians bill professional services on the CMS-1500 claim form.
- 2. Hospitals bill for services on the UB-92 claim form.

# B. Diagnosis Codes

Providers must bill the ICD-9-CM diagnosis code to the highest level of specificity that supports medical necessity for pancreas transplant (PTA).

# C. Procedure Codes

Codes that are covered include:

| 48554 | 48556 | 50300 | 50320 |
|-------|-------|-------|-------|
| 50340 | 50360 | 50365 | S2065 |

**D.** Providers must bill their usual and customary charges.